Jefferies resumed coverage on The Oncology Institute with a new price target
$TOI
Medical/Nursing Services
Health Care
Jefferies resumed coverage of The Oncology Institute with a rating of Buy and set a new price target of $2.50
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/15/2025 | $7.00 | Buy | BTIG Research |
| 2/26/2024 | $2.50 | Buy | Jefferies |
| 9/14/2022 | $7.00 | Buy | Guggenheim |
| 8/15/2022 | $10.00 | Buy | Jefferies |
4 - Oncology Institute, Inc. (0001799191) (Issuer)
3 - Oncology Institute, Inc. (0001799191) (Issuer)
4 - Oncology Institute, Inc. (0001799191) (Issuer)
CERRITOS, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. and its affiliates (NASDAQ:TOI) is pleased to announce the appointment of Jordan McInerney as the new Chief Development Officer (CDO), effective April 1, 2024. In this role, Mr. McInerney will spearhead growth initiatives for The Oncology Institute across diverse markets, including cultivating new partnerships with payors, driving M&A processes for acquisition targets, and establishing MSO platforms to deliver value-based oncology care nationwide. Bringing over 15 years of healthcare leadership, McInerney most recently served as the Chief Operations Officer of HOPCo Network Solutions, a subsidiary of Hea
CERRITOS, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) has announced the appointment of Jeremy Castle, MBA, as Chief Operations Officer, effective September 5, 2023. In this role, Mr. Castle leads enterprise field and central operations, pharmacy, real estate, and practice integration, playing a key role in driving TOI's success as a public company. Mr. Castle joins TOI with over 15 years of oncology industry experience, and has a track record of driving growth and profitability for multi-state physician groups. He has had other senior leadership positions, including Mr. Castle having previously served as the Chief Operating Officer for United Urolog
CERRITOS, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today announced that, by mutual agreement with the Board of Directors, Brad Hively will step down as Chief Executive Officer effective June 30, 2023. Dr. Daniel Virnich, the current President of TOI, will become CEO. Mr. Hively will transition to the role of Vice Chairman of the Board of Directors. Dr. Daniel Virnich has been with The Oncology Institute since 2020, initially as Chief Operating Officer before being promoted to President. He joined TOI from DaVita where he was most recently Pres
CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2025. Recent Operational Highlights Retail Pharmacy and Dispensary set fill records, contributing $49.3 million revenue and over $9 million in gross profit in Q1. The Pharmacy and Dispensary segment grew over 20% in the first quarter of 2025 vs. prior yearFee-for-service growth of 9% in Q1 2025 over Q4 2024, highlighting the impact of our investments in referral relationship management and call center expansion.Strong start
CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI"), one of the largest value-based oncology groups in the United States, announced today that Dr. Jeffrey Langsam will assume the role of enterprise Chief Clinical Officer effective May 13th, 2025. The CCO role will oversee therapeutics including pathway and procurement decisions, utilization management, and MSO practice clinical engagement. Dr. Langsam joins TOI from Cigna Healthcare, where he was the National Director of Oncology and a Senior Medical Director in the Specialty Pharmacy Division. He previously served as a Regional Medical Director at Aetna, and was clinical faculty at the Univ
CERRITOS, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI"), one of the largest value-based oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in B. Riley's 25th Annual Institutional Investor Conference in Marina Del Rey, CA on May 21st, 2025. About The Oncology Institute Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of over 1.8 million patients including clinical trials, transfusions, and ot
CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2025. Recent Operational Highlights Retail Pharmacy and Dispensary set fill records, contributing $49.3 million revenue and over $9 million in gross profit in Q1. The Pharmacy and Dispensary segment grew over 20% in the first quarter of 2025 vs. prior yearFee-for-service growth of 9% in Q1 2025 over Q4 2024, highlighting the impact of our investments in referral relationship management and call center expansion.Strong start
CERRITOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its first quarter 2025 financial results after the market close on Wednesday, May 14, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and t
CERRITOS, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2024. Recent Operational Highlights Cash flow from operations in Q4 2024 was approximately $4.2 million, due to disciplined working capital management that saw improvements across receivables, inventory, and payables.Selling, general, and administrative expenses decreased 12% in Q4 2024 as compared to the prior year period, as a result of our ongoing efforts to streamline operations, improve efficiency, and o
BTIG Research initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $7.00
Jefferies resumed coverage of The Oncology Institute with a rating of Buy and set a new price target of $2.50
Guggenheim initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $7.00
144 - Oncology Institute, Inc. (0001799191) (Subject)
8-K - Oncology Institute, Inc. (0001799191) (Filer)
EFFECT - Oncology Institute, Inc. (0001799191) (Filer)
4/A - Oncology Institute, Inc. (0001799191) (Issuer)
4 - Oncology Institute, Inc. (0001799191) (Issuer)
4 - Oncology Institute, Inc. (0001799191) (Issuer)
SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)
SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)
SC 13G/A - Oncology Institute, Inc. (0001799191) (Subject)